Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
University of Groningen · Showa University · +13 more institutions
Indexed incrossrefpubmed
Abstract
Background
Although inhibitors of the renin-angiotensin-aldosterone system can slow the progression of diabetic kidney disease, the residual risk is high. Whether nuclear 1 factor (erythroid-derived 2)-related factor 2 activators further reduce this risk is unknown.
Methods
We randomly assigned 2185 patients with type 2 diabetes mellitus and stage 4 chronic kidney disease (estimated glomerular filtration rate [GFR], 15 to
Citation impact
986
total citations
- FWCI
- 42.89
- Percentile
- 100%
- References
- 24
Citations per year
Authors
20Topics & keywords
Topics
Keywords
- Medicine
- Kidney disease
- Type 2 diabetes
- Diabetes mellitus
- Internal medicine
- Renin–angiotensin system
- Risk factor
- Endocrinology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.